Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study

摘要: Background In comparison with treatment unfractionated heparin (UFH) and aspirin (ASA), both tirofiban administered UFH ASA, enoxaparin plus ASA have shown superiority in reducing cardiac ischemic events patients unstable angina non-ST-segment elevation myocardial infarction. Replacing when is to may offer further therapeutic benefit, but could also increase bleeding. Objective Our objective was provide estimates of the frequency bleeding complications, as defined by means Thrombolysis Myocardial Infarction(TIMI) group, collect data on clinical efficacy combination ASA. Methods Five hundred twenty-five UA/NSTEMI were treated coadministered randomized receive either (n = 210) or 315). Therapy for 24 96 hours. Bleeding incidences assessed until hours after trial therapy discontinued; other outcomes long 30 days. Results The total rate (TIMI major + minor loss-no-site) group versus 4.8% vs 3.5% (odds ratio [OR] 1.4, CI 0.6-3.4). TIMI rates groups 1.0% 0.3% (OR 3.0, 0.3-33.8) 4.3% 2.5% 1.7, 0.7-4.6). There an nuisance cutaneous oral bleeds (<50 mL blood loss) group. Death infarction occurred similar 2 (9.0% 9.2%). However, refractory ischemia requiring urgent revascularization rehospitalization because more frequently (4.3% 0.6% 7.1% 1.6%, respectively). Conclusions Combination appears safe, relative UFH. (Am Heart J 2002;144:470-7.)